Article | March 29, 2023

Evolution Of A Novel Polymer To Overcome Limitations In Sustained Drug Delivery In Ophthalmology


Blindness and vision impairment pose an enormous burden on patients, but challenges specific to the physiology of the eye — the retina-blood barrier and the rapid clearance of the medicine from the intravitreal space — complicate the development of new therapies and necessitate innovative drug delivery methods. Current delivery methods for retinal diseases often entail local needle injections, causing significant discomfort and undesired side-effects. Biodegradable, locally applied drug delivery systems offer a more accessible, and ultimately effective, alternative to treat chronic eye conditions.

However, the eye is an immune privileged site in the body, a feature which defends the eye function but presents a challenge for the bio-erosion of an enzymatically degradable material. As a result, a hydrolytically degradable drug delivery carrier is preferred for ophthalmic applications. The molecular structure in DSM Biomedical’s TheraPEA™ polymer enables degradation while still preserving material biocompatibility and drug release properties, positioning it as a promising excipient for drug delivery solutions in ophthalmology.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online